Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

被引：0

作者：

Powles, T. ^{[1
]}

Motzer, R. J. ^{[2
]}

George, D. J. ^{[3
]}

Jonasch, E. ^{[4
]}

Pal, S. ^{[5
]}

Tannir, N. M. ^{[4
]}

Signoretti, S. ^{[6
]}

Mai, T. H. ^{[7
]}

Scheffold, C. ^{[8
]}

Wang, E. ^{[9
]}

Aftab, D. T. ^{[10
]}

Escudier, B. ^{[11
]}

Choueiri, T. K. ^{[12
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[3] Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[5] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA

[6] Brigham & Womens Hosp, Pathol, 75 Francis St, Boston, MA 02115 USA

[7] Ann Arbor Pharmacometr Grp, Pharmacometr, Ann Arbor, MI USA

[8] Exelixis Inc, Clin Dev, San Francisco, CA USA

[9] Exelixis Inc, Translat Med, San Francisco, CA USA

[10] Exelixis Inc, Execut Adm, San Francisco, CA USA

[11] Gustave Roussy, Med Oncol, Villejuif, France

[12] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

872P

引用

页数：2